Existing investors provide funding to finish international RESPONDER-HF trial 

TEWKSBURY, Mass., June 17, 2025 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from the company’s existing investment syndicate of Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two strategic investors.

The funds will be used to complete the ongoing RESPONDER-HF trial, a double-blinded, randomized, sham-controlled, confirmatory trial of the Corvia^® Atrial Shunt currently underway at more than 65 institutions on three continents. The study is expected to generate the final supportive clinical data required for FDA approval of the shunt as a breakthrough treatment for heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF).

“We are profoundly grateful for the unwavering support of our longstanding investors as we advance toward FDA submission of the Corvia Atrial Shunt,” said George Fazio, CEO of Corvia Medical. “Their commitment furthers our mission to bring this transformative heart failure treatment to millions of patients worldwide.”

Paul LaViolette, Board Chair of Corvia Medical, added, “We firmly believe Corvia has the potential to fundamentally alter the landscape of heart failure treatment, and our investors share that vision. With these resources, we are well-equipped to drive the company through the approval process and introduce this groundbreaking therapy to the market.”

About heart failure (HF) and the Corvia Atrial Shunt

More than 26 million people worldwide have HF, and the majority have HFpEF, making it the largest unmet clinical need in cardiovascular medicine. The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary contributor to HF symptoms, by creating a passage between the left and right atria, reducing HF events and improving quality of life. The Corvia Atrial Shunt was granted Breakthrough Device designation by the FDA in 2019. For information regarding RESPONDER-HF study eligibility, please visit https://treatmyheartfailure.com.

About Corvia Medical, Inc.

Corvia Medical, Inc. is revolutionizing the treatment of heart failure through novel transcatheter cardiovascular devices. Founded in 2009 and headquartered in Tewksbury, MA, privately-held Corvia is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. Visit https://corviamedical.com.

MEDIA CONTACT:
Lisa Ensz
+1 978-654-6120
[email protected]

SOURCE Corvia Medical, Inc.

TOKYO, June 16, 2025 — Following the successful launch of its inaugural program, JETRO and Coolwater Capital are proud to announce Cohort 2 of the Emerging Fund Manager Accelerator. This initiative aims to equip Japan’s next generation of venture capitalists with the tools and global perspective needed to build institutional-grade, globally competitive funds.

The first cohort saw 17 GPs selected from hundreds of applicants across Japan, collectively targeting over $500M in fundraising. Highlights included in-depth training from leading U.S. VCs, a 125-person Japan Innovation Summit in San Francisco, and in-person visits to Tier 1 VC firms—marking a breakthrough in cross-border knowledge sharing.

“We saw real traction—new fund launches, global LP engagement, and deep peer connections,” said Winter Mead, Founder & CEO of Coolwater Capital. “Cohort 2 is about scaling that impact and deepening the infrastructure for Japan’s VC future.”

JETRO echoed this sentiment:

“The results of Cohort 1 proved Japan’s potential on the global VC stage,” said Tatsuhiko Shiono, Director of JETRO Startup. “We’re thrilled to deepen our collaboration with Coolwater and help more fund managers go global.”

What’s New in Cohort 2:

• Enhanced 1:1 fundraising and brand coaching
• Expanded shared services (LP strategy, IR, positioning)
• More localized support with hybrid delivery
• New podcast and content community for alumni

Key Dates:

• Applications open: June 11, 2025
• Deadline to apply: July 16, 2025
• Program launch: September 9–11 in Tokyo, followed by weekly virtual modules
• Capstone: Coolwater Investor Summit, November 17–19 in New York

The 3-month accelerator includes 8 modules plus networking events, office hours, and meetups. All programming is in English, with support for both in-person and online participation.

Who Should Apply:

Emerging VC managers, ex-founders, corporate spinouts, tech executives, and institutional investors with bold, Japan-focused investment theses.

About Coolwater Capital
Founded in San Francisco, Coolwater has supported over 300 emerging funds globally, helping raise $5B+ and back more than 8,400 startups.

About JETRO
The Japan External Trade Organization (JETRO) is a government agency committed to promoting innovation and supporting global trade and investment.

SOURCE Coolwater Capital

DENVER, June 16, 2025 — Colorado Energy Office (CEO) has awarded Liberty Schools J-4 School District a total of $1.9M in funding as part of a State initiative to support geothermal HVAC projects across Colorado.

Funding from CEO was made available through three sources; The Geothermal Energy Grant Program (GEGP); The Geothermal Energy Tax Credit Offering (GETCO); and The Public Buildings Electrification Grant (PBEG). The district received funding from all three sources.

GEGP and GETCO funding is specifically designated for HVAC renovations that utilize geothermal technology. The awarded PBEG funds will support the cost of transitioning from fossil fuels to high-efficiency electric heat pumps that will serve as the building’s primary heat source.

Liberty School District selected Millig Design Build as their comprehensive turnkey service provider. Millig will be responsible for the complete project cycle; including initial design development, full-scale implementation of the geothermal HVAC systems, and ongoing post-construction support.

“Partnering with Millig Design Build from the onset of this project has been seamless and the best decision for our district” said Rhonda Puckett, Liberty’s Superintendent, “Millig was instrumental in securing nearly $2M in grant funding through the Colorado Energy Office. Millig guided Liberty School District through every step of the process, and we truly could not have done any of this without them. It’s clear that Millig understands the unique needs of our district and has truly invested in our school and our vision for a sustainable future.”

Liberty School’s facilities currently include several failing systems that require immediate attention. These include a completely failed gymnasium’s heating unit and an outdated hydronic system. Additionally, the absence of both a cooling system and a ventilation system raises concerns about the comfort, health, and safety standards within the building.

“Unfortunately, hydronic heating systems in these older school buildings were not designed for adequate cooling or ventilation, a challenge Liberty School District has faced for many years,” said Aaron Tilden, PE, Senior Project Developer, Millig Design Build. “We are proud to be selected as their turnkey service provider for this crucial initiative. It is time to bring this facility into the 21st century with a state-of-the-art ground-source HVAC system that will help provide a healthy, safe, and comfortable learning environment.”

The Millig team performed a thorough facility analysis and is moving forward with plans to install a new Ground-Coupled Variable Refrigerant Flow system which will provide energy-efficient heating and cooling, while Energy Recovery Ventilators will ensure optimal indoor air quality and a new Packaged Rooftop Unit for the gymnasium will address the previous heating unit failure.

The project will be completed in two phases, all construction is scheduled to be completed by Fall of 2025.

About Millig Design Build
Millig Design Build is an integrated engineering, design, and construction firm specializing in turnkey facility improvements that address energy efficiency, building health and safety, and core infrastructure needs. We serve clients nationwide from four strategic offices in Kansas; Colorado; Oregon; and Washington; For more information, visit milligdb.com

Media Contact Information:
Veronica Guerrero | [email protected]

SOURCE Millig Design Build

SHANGHAI, June 16, 2025 — Med-Fine Capital, a VC firm focused on investing in early-stage healthcare innovation in China, has announced successful close of its second USD fund. The fund will continue investing in cutting-edge biotech startups and supporting next-gen healthcare related technologies.

Investor Confidence Despite Market Challenges

This successful fundraising comes at a pivotal moment, as China’s biotech investment market undergoes a period of adjustment. Jack Zhou, Managing Partner of Med-Fine Capital, stated, “In the current environment, the continued trust and support from our investors are particularly valuable. It is not only a recognition of our past performance and professional capabilities, but also a strong endorsement of our commitment to Med-Fine’s global development strategy.”

Med-Fine Capital remains optimistic about the future:

1.  China’s Rising Innovation Strength: From 2015 to 2024, the number of innovative drugs from China receiving first-time global approval increased from 3 to 39, a 12-fold rise, elevating China from the 3^rd to 2^nd place worldwide. Simultaneously, Chinese biotech companies have accelerated global expansion through cross-border BD transactions, reaching a total transaction value of USD 63.5 billion in 2024 (up 22.59% YoY), with 24 mega-deals (over USD 1 billion each) totaling USD 43 billion, nearly 20% of the global total.

2.  Rebound of the Hong Kong Capital Market: In May 2025, IPO proceeds in the Hong Kong stock market reached HKD 55.8 billion, the highest since March 2021. Year-to-date fundraising has reached HKD 77.4 billion, nearly 90% of the 2024 full-year total. The Hang Seng Tech Index rose by 14.9%, significantly outperforming other major global markets.

3.  Exceptional Investment Capability: The Med-Fine Capital team combines deep industry knowledge, a strong global network, and proven investment capabilities.

A Decade of Focus on Early-Stage Innovation

In the past decade, Med-Fine Capital has consistently focused on the Chinese biotech innovation ecosystem, guided by its investment philosophy of discovering early-stage opportunities and helping them grow. The firm has invested in more than 60 innovative startups so far. This newly raised fund is Med-Fine’s second USD fund, marking its establishment and steady growth in the USD investment market. LPs include global renowned FOF, Hong Kong financial institutions, Singaporean family offices, and corporations in the healthcare sector.

Backing Startups with a Global Edge

“Med-Fine Capital’s investment team possesses strong industry expertise and connections, in addition to a wealth of global experience and perspective,” said Dr. Vince Deng, Partner and Head of Biotech Investment at Med-Fine Capital. “Our focus areas include oncology, autoimmune, metabolic and CNS diseases, where we invest in globally competitive and differentiated innovation. We actively support promising Chinese biotech companies to go global, helping them in all important aspects including R&D, clinical development, and regulatory affairs during their global expansion.”

Med-Fine Capital’s approach is not only about early and precise investment. It emphasizes on deep and hands-on support to entrepreneurs to achieve exceptional return. Staying true to a “begin with the end in mind” philosophy, the firm works backward from market demand and exit possibilities to shape company development. “Med-Fine pays special attention to co-founding new ventures with serial entrepreneurs and selecting highly promising directions and assets in the right time and fashion, to reduce investment risk and create maximum return. We have already co-founded and invested in several highly promising biotech companies through the above-mentioned investment philosophy and approach in this USD fund, including Allink Biotherapeutics and VelaVigo. Most of them have already secured one or more arounds of follow-on funding led by top-tier investors. These outcomes strengthen our confidence and encourage us to keep doing what we have done again and again,” added Dr. Vince Deng.

Long-Term Partners, Global Vision

Mr. Jack Zhou emphasizes, “Med-Fine Capital is dedicated to investing in globally competitive pipeline assets. We are not just capital providers but aim to be long-term strategic partners to our portfolio companies. Our goal is to build a research-driven investment system rooted in clinical value and technological innovation, with global market value in mind and meeting unmet medical needs as the end game. We continuously strengthen our core competencies in cross-border resource integration and cross market cycle value investment to help patients globally living a better life.”

About Med-Fine Capital

Med-Fine Capital specializes in investment in healthcare and life sciences. The management team boasts a global perspective, deep industry expertise, extensive resources, and professional investment experience. Med-Fine manages several RMB and USD funds, focusing on early-stage value discovery in biotech, device, diagnostics, digital health and healthcare services. To date, Med-Fine has invested in more than 60 companies, including Mabworks, Eccogene, Zion, LYNK, Pharma Legacy, MagAssist, Alebund, Allorion, ImmVira, Degron, Allink and Castalysis.

SOURCE Med-Fine Capital

$130 million in new funding will fuel investment in JunieAI: enterprise-grade AI for private markets GPs

SAN FRANCISCO, June 16, 2025 — Juniper Square, the pioneer of connected fund software and services for private markets, today announced it closed its Series D round and secured $130 million in new funding led by Ribbit Capital, with significant strategic investment from Fifth Wall, and additional participation from Redpoint Ventures, HighSage Ventures, Blue Owl Capital and others.

Juniper Square will use the capital to accelerate investment in JunieAI—the first enterprise-grade AI built specifically for the needs of private markets GPs. JunieAI combines the power of modern large language models (LLMs) with critical enabling components—Juniper Square’s fund system of record for GPs and LPs, a scaled data model, comprehensive workflows coupled with managed services, industry integrations, and robust measures for security, control, and permissioning—to help GPs move faster, work smarter, and operate more efficiently.

As an agentic AI platform, JunieAI provides:

• Agents supporting the work of investor relations, fund administration, portfolio management, and investment decisions
• Model-agnostic orchestration across agents, tools, workflows, and systems
• Precision tools for the accuracy demands of accounting and reporting, fused with the ease of use and power of generative AI
• Secure, enterprise-grade permissioning and control
• Deep domain expertise in private markets
• AI workflows wrapped with full service solutions
• Unified structured and unstructured data—including from emails and documents
• Seamless integration with existing GP tools
• Fine-grained agent governance, empowering GPs to define how AI agents behave, respond, and defer across use cases

“The private markets are undergoing a once-in-a-generation transformation driven by two tsunamis of change: the rise of the retail investor and the breakthrough potential of AI,” says Alex Robinson, CEO and Co-Founder at Juniper Square. “Our mission is to equip GPs with the technology and services they need to thrive in this new era. With JunieAI, we’re helping our customers stay ahead—turning disruption into opportunity across every facet of work inside of the modern GP.”

“Juniper Square is uniquely positioned to lead the private markets into the AI era,” says Nick Shalek, General Partner at Ribbit Capital. “Few companies have the combination of enterprise-grade trust, enabling infrastructure, deep domain expertise, and structured data at scale that Juniper Square brings to bear. With JunieAI, they’re harnessing these strengths to build AI solutions that are purpose-built for private markets—not just bolted on. We’re thrilled to support Juniper Square as it sets the standard for how this industry will evolve.”

This fundraise follows a period of rapid growth for Juniper Square including >100% 3-year CAGR in its fund administration business, which today manages over 2,000 fund entities globally across an extensive range of strategies and complex fund structures. Growth has been especially strong in the private equity and venture capital verticals, which now represent four of the five largest customers by revenue. In May, Juniper Square expanded into Luxembourg, unlocking integrated fund administration and efficient cross-border operations for private markets GPs at a global scale.

“Juniper Square stands out as a frontrunner to lead the private markets as the world moves toward an AI-driven future,” says Jay Maher, Global Chief Operating Officer at H.I.G. Capital. “Juniper Square’s focus on AI innovation will deliver transformative benefits across the industry—empowering organizations to better serve investors and drive long-term growth.”

Over the past decade, Juniper Square has built the connected infrastructure that powers private markets, helping make the industry more efficient, transparent, and accessible. With retail investors reshaping the landscape and the market on track to exceed $60 trillion within a decade, GPs need innovations like JunieAI to keep pace and capture new opportunities.

We invite you to join Alex Robinson, CEO and Co-Founder, and Brandon Rembe, Chief Solutions Officer, for a Virtual Keynote on June 23 at 9:00 a.m. PT where they’ll share more about JunieAI and Juniper Square’s vision for private markets AI innovation – register here.

More information about Juniper Square and JunieAI can be found here.

About Juniper Square
Juniper Square is transforming the private markets investing experience with a full range of modern, connected fund software and services. More than 2,000 private markets GPs rely on Juniper Square to support their fundraising, reporting, fund administration, treasury, compliance, and business intelligence needs across more than 40,000 funds, 600,000 LP accounts, and $1 trillion of LP capital.

SOURCE Juniper Square

NEW YORK, June 16, 2025 — In a $185 billion U.S. apparel e-commerce industry saturated with choice and friction, Alta is crafting a brand new AI-native shopping experience by empowering shoppers with a personalized styling companion.

Alta announced today it has raised $11 million in seed funding to build the next generation of personal shopping and styling—powered by AI.

The round was led by Menlo Ventures with participation from Aglaé Ventures (an investment firm  backed by the Arnault family), Benchstrength Ventures, Conviction, Phenomenal Ventures, and a notable group of celebrity stylists, consumer tech founders, and AI experts, including Tony Xu, Karlie Kloss, Jasmine Tookes, Meredith Koop, Keltie Knight, Gabriel Whaley, Zita D’Hauteville, Kelvin Beachum Jr., Amjad Masad, Jenny Fleiss, and Manish Chandra. Menlo Ventures Partner Amy Wu is joining the board.

Alta’s core product is an AI stylist and personal shopper that creates shopping and outfit recommendations based on a user’s closet, lifestyle, budget, occasion, and weather. The app leverages over a dozen proprietary multimodal generative AI models, all trained in-house on fashion data. In addition to personalized outfit curations and shopping suggestions, users can try-on recommended outfits on their virtual avatar—including mixing and matching shoppable items with their own closet items. Alta’s virtual dressing room offers users an immersive and novel retail experience.

“We built Alta to make personal style effortless and fun—with an AI that truly understands you,” said founder Jenny Wang. More recently, the Council of Fashion Designers of America (the CFDA) announced a partnership with Alta.

“For years, personalized styling was a luxury reserved for the rarest occasions. Alta is breaking that mold with AI models that can decode fashion and understand personal taste at scale,” said Amy Wu, Partner at Menlo Ventures. “We were looking to work with a founder who could bridge deep technical expertise with an intuitive grasp of fashion and consumer behavior. Jenny Wang is exactly that. We’re thrilled to back her and join Alta’s journey to reimagine how people shop and dress.”

Alta’s mission is simple: to help everyone look and feel their best. The funding will accelerate Alta’s product development, expand its AI capabilities, and grow its team across engineering and operations.  For more information, visit altadaily.com, follow @alta on Instagram, or download the Alta app from the App Store.

For Media Inquiries:
[email protected]

SOURCE Alta Daily

Former Head of Health investments at Leaps by Bayer brings extensive biomedical innovation and venture capital experience to help catalyze impact-driven growth for the T1D community

The latest in a string of strategic hires signifying a new chapter for the Fund aimed at higher-conviction investments for greater mission impact

BOSTON, June 16, 2025 — The T1D Fund: A Breakthrough T1D Venture, LLC, an impact investment fund focused on accelerating life-changing solutions to treat, prevent, and ultimately cure type 1 diabetes (T1D), today announced the appointment of Lucio Iannone, Ph.D., as its new Managing Director starting the beginning of August. With a dual background as biopharma investor and scientist, Iannone will draw upon his successful track record in dealmaking and pipeline development to help drive the Fund’s impact investment strategy, including aiding in the establishment of deal flow, fine-tuning optimal investment approaches, and providing meaningful portfolio company support. 

“Lucio’s appointment marks a pivotal moment for the T1D Fund, as we welcome a highly esteemed investment veteran to our ranks,” said Elizabeth Mily, CEO of the T1D Fund. “He will play a crucial role as we pursue the next wave of groundbreaking treatment within T1D, ensuring our dollars have a greater impact by accelerating high-potential programs and catalyzing new opportunities that are on the precipice of breakthroughs. His background in leading the generation and execution for more than 25 deals, combined with his scientific expertise, uniquely positions him to identify and support innovative companies pursuing potential cures. Building a world-class investment team to deploy in our mission of broadening industry efforts towards T1D is one of my top priorities as CEO, and Lucio’s hire is a key step toward achieving that goal.”

Iannone joins the Fund after serving as Head of Health Investments USA for Leaps by Bayer, the strategic investment arm of Bayer AG. At Leaps, he led and mentored the global investment team, driving strategic and deal execution, overseeing more than 25 biomedical investments and directing assets under management exceeding $1 billion. With expertise in oncology, autoimmune disease, cell and gene therapies, and chronic conditions, he has a deep understanding of scientific, clinical, and commercial dynamics that will directly benefit the Fund’s mission. Iannone earned his Ph.D. in Medicine at Imperial College of London, and has served on the boards of innovative companies such as Mozart Therapeutics, eGenesis Biosciences, Immunitas Therapeutics, and more.

“The T1D therapeutic landscape is ripe for innovation, and I’m eager to join the Fund’s efforts to identify, support, and direct funding to companies with curative potential,” said Iannone. “Together with this dynamic team and our network of partners, we will execute an expansive strategy to further elevate groundbreaking scientific discoveries and accelerate therapies that can transform the lives of individuals with T1D.”

Iannone’s hiring is the latest in a string of strategic appointments by the Fund, signaling a new chapter of impact investing. This infusion of expertise will help strengthen the Fund’s ability to serve as a preferred investor and partner, yielding greater program advancement, significant investment in T1D, and an amplified mission impact—further solidifying its position as the leading catalyst for the development of T1D cure-oriented therapies.

About the T1D Fund: A Breakthrough T1D Venture, LLC
Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease-modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions. Learn more at t1dfund.org. Follow the T1D Fund on Linkedin.

Media Contact
Lia Dangelico
[email protected]
540-303-0180 

SOURCE The T1D Fund

SALT LAKE CITY, June 16, 2025 — Lumion, the company building the most comprehensive operating system for career and trade schools, today announced it has raised a total of $10.7 million in seed funding led by TTV capital with recent participation from Tusk Venture Partners. The round also includes prior support from TTV Capital, CreativeCo Capital, Nine Four Ventures, Innovating Capital, and the State of Wyoming.

The funding comes amid a pivotal moment for the U.S. workforce. As the country faces a critical skilled labor shortage, enrollment growth in trade and technical programs is outpacing that of four-year colleges. Lumion is emerging as the infrastructure layer that enables schools to meet that demand, streamlining student acquisition, operations, and outcomes from end to end.

“Trade schools have been stuck managing mission-critical processes across spreadsheets, disconnected CRMs, and legacy student information systems (SISs),” said Joshua Hagani, CEO of Lumion. “We’ve built the ultimate platform to unify the full student experience from lead capture all the way through alumni tracking.”

Originally focused on student financing, Lumion has evolved into an All-in-one SaaS platform enabling trade and technical schools to grow efficiently and serve more students. Over the last year, the company has tripled its revenue, customer base and team, supporting over 100,000 students across 260+ partner schools in more than 29 industries.

The new Lumion Platform includes three major product lines:

• Enrollment: Schools can now generate and manage prospective student leads from their own website, funneling them into a centralized enrollment flow with applications, communication, scheduling and onboarding capabilities.
• Payments: Once a lead is captured and nurtured, students are guided through all available payment options including upfront payment, a lender marketplace, and school-administered payment plans ensuring increased enrollment, retention, and collection. Lumion handles all collections and servicing on behalf of schools.
• Full-Service SIS Capabilities: Lumion provides centralized comprehensive reporting of all student activities and interactions, bringing clarity and insights to school operators.

Lumion brought in Tusk Venture Partners to top off its seed round due to surplus investor demand in late 2024, accelerating market expansion and continuing product innovation.

To date, Lumion has:

• Processed over 140,000 tuition payments
• Enabled 1,690 school administrators
• Delivered an estimated $20 billion in human capital impact
• Grown to a 35-person team headquartered in Salt Lake City

With government policy tailwinds behind workforce development and a broken traditional higher education model, Lumion is the operating system of choice for trade & technical schools.

About Lumion
Lumion is the all-in-one platform for trade and technical schools, streamlining the full student lifecycle from lead generation and tuition payments to enrollment, reporting, and alumni tracking. Headquartered in Salt Lake City, Lumion is building the infrastructure for the future of skilled education. Learn more at joinlumion.com.

SOURCE Lumion

Highlights:

• Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor in connection with public warrant exercises.
• Update on NASDAQ Compliance: Klotho believes it now exceeds the stockholders’ equity thresholds required to remain in compliance with NASDAQ listing requirements.
• Zero Debt: Klotho has fully extinguished all outstanding debt, resulting in a debt-free balance sheet.

NEW YORK, June 16, 2025 — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised over $11 million in funding through the exercise of existing warrants by investors. The Company believes that it now surpasses Nasdaq’s stockholders’ equity requirement requirements outlined in its Nasdaq compliance plan.

In addition, the Company utilized  $3.1 million of the funds raised to extinguish all outstanding debt, resulting in a debt-free balance sheet.

About Klotho Neurosciences, Inc. 
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using an important human protein derived from the Company’s patented form of the “anti-aging” human Klotho gene (s-KL) and its novel promoter and delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, contact:
Investor Contact and Corporate Communications – Jeffrey LeBlanc, CFO
[email protected]

Website: www.klothoneuro.com

Forward-Looking Statements:

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

SOURCE Klotho Neurosciences, Inc.